RxDoctor Payments Data

Joseph Jackmovich, DO

Psychiatry · Medford, ORNPI 1992326987

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $862 of the $973 with a category attached, or 88.5%. 12 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 28.8% of the total. 2025 is the largest year on record at $699, more than ten times the $49 reported in 2021. Among psychiatry clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$973in general payments, 2019–2025

Across 35 payments — averaging $27.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$280
  • Axsome Therapeutics, Inc.$173
  • Teva Pharmaceuticals USA, Inc.$147
  • E.r. Squibb & Sons, L.L.C.$100
  • Alkermes, Inc.$88
  • Vanda Pharmaceuticals Inc.$36
  • plus $148 from 6 others

What the payments were for

  • Food & beverage$86289%
  • Education$11111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$973 in reported general payments places this provider in the 90th percentile of 366 psychiatry providers in Oregon.

See all psychiatry providers in Oregon

Medicare billing

Part B allowed, 2024
$13,955
Medicare patients
44
Services billed
90

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole12$37,332
Mirtazapine40$772
Olanzapine OdtOlanzapine11$526
Bupropion XlBupropion Hcl22$433
Hydroxyzine Hcl17$396
Duloxetine Hcl23$377
Aripiprazole23$353
Trazodone Hcl46$268
Lamotrigine31$254
Sertraline Hcl14$241
Guanfacine Hcl ErGuanfacine Hcl18$179
Clonazepam21$177
Prazosin Hcl13$170
Divalproex Sodium11$155
Buspirone Hcl16$147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$280$37,33212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 366 psychiatry providers in Oregon.

Other psychiatry in Medford

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →